The results of a recent randomized controlled phase 2 trial of HCQ in 35 patients with various forms of fibrosing chILD conditions, including 5 patients with ABCA3 deficiency, did not identify an overall HCQ treatment effect [9]. Here, ABCA3 is linked to interstitial lung disease specific to childhood.